Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.15Last Year’s EPS
0.14Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -18.68%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call for ADMA Biologics reflected strong financial growth and operational achievements, notably with the FDA approval for a new production process and raised financial guidance. However, challenges such as voluntary product withdrawals and high operating expenses were also evident. Overall, the sentiment remains optimistic, supported by strategic initiatives and financial strength.Company Guidance
During ADMA Biologics' first quarter 2025 conference call, the company announced a significant financial and operational upturn, with total revenues reaching $114.8 million, reflecting an impressive 40% year-over-year growth. The adjusted net income and adjusted EBITDA surged by approximately 87% and 81% year-over-year, respectively. In light of these robust results, ADMA revised its 2025 guidance, projecting total revenues of $500 million or more, adjusted EBITDA of at least $235 million, and reaffirmed adjusted net income guidance of at least $175 million. For 2026, expectations were increased to $625 million in total revenue, $340 million or more in adjusted EBITDA, and adjusted net income of at least $245 million. The company also anticipates reaching $1.1 billion in total annual revenue before 2030. Additionally, ADMA announced a $500 million stock repurchase program, emphasizing its strategic capital allocation and commitment to enhancing shareholder value. The company's confidence is further bolstered by its FDA-approved yield enhancement production process, enabling a 20% increase in bulk IG production from the same plasma volumes, positioning ADMA as a leader in the plasma-derived therapies market.Strong Financial Growth
Total revenues reached $114.8 million, a $32.9 million increase year-over-year, marking a growth rate of approximately 40%. Adjusted EBITDA grew by approximately 81% year-over-year. Adjusted net income increased by 87% year-over-year.
FDA Approval for Yield Enhancement Process
ADMA received FDA approval for a novel yield enhancement production process, which is expected to provide 20% more bulk IG from the same starting plasma volumes.
Raised Financial Guidance
Guidance for 2025 and 2026 was raised, with 2025 total revenue guidance increased to $500 million or more, and 2026 total revenue guidance increased to $625 million or more.
Stock Repurchase Program
The Board authorized a stock repurchase program allowing ADMA to purchase up to $500 million of its common stock, approximately 8% of the company’s total current market cap.
Debt Reorganization
Debt reorganization with Ares Capital Management was completed, reducing the total cost of debt by 1.1%.
---
ADMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $23.61 | $21.20 | -10.21% |
Mar 03, 2025 | $15.83 | $17.01 | +7.45% |
Nov 07, 2024 | $19.72 | $22.62 | +14.71% |
Aug 08, 2024 | $12.19 | $15.96 | +30.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ADMA Biologics (ADMA) report earnings?
ADMA Biologics (ADMA) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is ADMA Biologics (ADMA) earnings time?
ADMA Biologics (ADMA) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADMA EPS forecast?
ADMA EPS forecast for the fiscal quarter 2025 (Q2) is 0.15.
---